Latest Research News from the Foundation for Women's Cancer and Society of Gynecologic Oncology

The BLA for zenocutuzumab to treat NRG1-positive non–small cell lung cancer and pancreatic cancer received priority review from the FDA.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

Tolerable anti-tumor activity was demonstrated in patients with HER2-overexpressing non–small cell lung cancer who were treated with trastuzumab deruxtecan at 2 dose levels.